IN2014DN10322A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10322A IN2014DN10322A IN10322DEN2014A IN2014DN10322A IN 2014DN10322 A IN2014DN10322 A IN 2014DN10322A IN 10322DEN2014 A IN10322DEN2014 A IN 10322DEN2014A IN 2014DN10322 A IN2014DN10322 A IN 2014DN10322A
- Authority
- IN
- India
- Prior art keywords
- drug
- molecule
- complementary
- water
- taxol
- Prior art date
Links
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647727P | 2012-05-16 | 2012-05-16 | |
| PCT/US2013/035792 WO2013172999A1 (fr) | 2012-05-16 | 2013-04-09 | Compositions pharmaceutiques pour l'administration de médicaments pratiquement insolubles dans l'eau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10322A true IN2014DN10322A (fr) | 2015-08-07 |
Family
ID=49584153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10322DEN2014 IN2014DN10322A (fr) | 2012-05-16 | 2013-04-09 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9895322B2 (fr) |
| EP (1) | EP2849770B1 (fr) |
| JP (1) | JP6247685B2 (fr) |
| AU (1) | AU2013263292B2 (fr) |
| CA (1) | CA2873572C (fr) |
| IN (1) | IN2014DN10322A (fr) |
| MX (1) | MX2014013826A (fr) |
| WO (1) | WO2013172999A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008130587A2 (fr) | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Réseaux de micro-aiguilles coulées dans un solvant contenant un actif |
| US8911749B2 (en) | 2007-04-16 | 2014-12-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
| CA2798145C (fr) | 2010-05-04 | 2022-10-18 | Corium International, Inc. | Methode et dispositif permettant l'administration transdermique d'hormone parathyroidienne au moyen d'un reseau de microprojections |
| IN2014DN10322A (fr) | 2012-05-16 | 2015-08-07 | Mewa Singh | |
| EP2934660B1 (fr) | 2012-12-21 | 2019-07-17 | Corium, Inc. | Micro-réseau pour la distribution d'un agent thérapeutique et son procédé de fabrication |
| CA3130120A1 (fr) | 2013-03-12 | 2014-10-09 | Corium, Inc. | Applicateurs de microprojection |
| ES2939317T3 (es) | 2013-03-15 | 2023-04-20 | Corium Pharma Solutions Inc | Aplicadores de microproyección de impacto múltiple |
| US10384045B2 (en) | 2013-03-15 | 2019-08-20 | Corium, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| EP2968118B1 (fr) | 2013-03-15 | 2022-02-09 | Corium, Inc. | Microréseau pour l'administration d'un agent thérapeutique et ses procédés d'utilisation |
| US10213391B2 (en) | 2014-05-06 | 2019-02-26 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
| WO2016036866A1 (fr) | 2014-09-04 | 2016-03-10 | Corium International, Inc. | Matrice de microstructures, procédé de production et procédés d'utilisation |
| US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
| US11622937B2 (en) * | 2015-08-20 | 2023-04-11 | Mewa Singh | Polyphenolic polymer to make water-insoluble molecules become water-soluble |
| WO2018118197A1 (fr) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Vieillissement en meilleure santé pour les animaux domestiques |
| BR112020021852A2 (pt) | 2018-05-02 | 2021-02-23 | Ferring B.V. | formulações farmacêuticas aperfeiçoadas |
| IL261132A (en) | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use |
| CN109806241A (zh) * | 2019-03-04 | 2019-05-28 | 聊城大学 | 一种双药白蛋白纳米粒及制备工艺 |
| US20240090561A1 (en) * | 2019-10-09 | 2024-03-21 | Nicoventures Trading Limited | Aerosolizable material |
| US20210393541A1 (en) * | 2020-06-19 | 2021-12-23 | City University Of Hong Kong | Preparation of nanoparticles using modified ice-template |
| CA3217137A1 (fr) | 2021-04-29 | 2022-11-03 | Christopher Adair | Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procedes de fabrication et leurs utilisations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| GB9405593D0 (en) | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
| US5731355A (en) | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
| ES2292233T3 (es) | 1998-02-10 | 2008-03-01 | Sicor Inc. | Composicion de propofol que contiene sulfito. |
| US6028108A (en) | 1998-10-22 | 2000-02-22 | America Home Products Corporation | Propofol composition comprising pentetate |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6100302A (en) | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
| JP2005529127A (ja) * | 2002-04-26 | 2005-09-29 | テバ ファーマシューティカル インダストリーズ リミティド | 腫瘍内送達のためのミクロ粒子製薬組成物 |
| KR20200083657A (ko) | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| EP1670516A2 (fr) * | 2003-09-30 | 2006-06-21 | Solubest Ltd | Nanoparticules hydrosolubles et leur procede de production |
| JP2009521396A (ja) * | 2005-03-31 | 2009-06-04 | スミスクライン・ビーチャム・コーポレイション | 溶解可能な歯のホワイトニングストリップ |
| GB2436745B8 (en) * | 2005-09-09 | 2019-03-13 | Jae Woon Nah | Method for enhancing the solubility of paclitaxel |
| GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| JP2010505877A (ja) * | 2006-10-05 | 2010-02-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | スマートな高分子ナノ粒子を用いた低水溶性薬物用の水分散性経口、非経口および局所的製剤 |
| US20120003177A1 (en) * | 2008-09-17 | 2012-01-05 | Youqing Shen | Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers |
| JP5539993B2 (ja) * | 2008-09-23 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 薬物送達のためのナノ担体 |
| US8735374B2 (en) | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US8501248B1 (en) | 2010-11-02 | 2013-08-06 | Seven Consulting, Inc. | Botanical composition and method for treating pain and discomfort of various conditions |
| BR112013032675A2 (pt) | 2011-06-19 | 2017-08-08 | Vaxine Pty Ltd | composição adjuvante de vacina compreendendo partículas de inulina |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| ES2739194T3 (es) | 2012-01-19 | 2020-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulación y método para aumentar la biodisponibilidad oral de fármacos |
| IN2014DN10322A (fr) | 2012-05-16 | 2015-08-07 | Mewa Singh |
-
2013
- 2013-04-09 IN IN10322DEN2014 patent/IN2014DN10322A/en unknown
- 2013-04-09 CA CA2873572A patent/CA2873572C/fr active Active
- 2013-04-09 JP JP2015512655A patent/JP6247685B2/ja active Active
- 2013-04-09 AU AU2013263292A patent/AU2013263292B2/en active Active
- 2013-04-09 MX MX2014013826A patent/MX2014013826A/es active IP Right Grant
- 2013-04-09 WO PCT/US2013/035792 patent/WO2013172999A1/fr active Application Filing
- 2013-04-09 EP EP13790330.8A patent/EP2849770B1/fr active Active
-
2014
- 2014-11-06 US US14/534,400 patent/US9895322B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9895322B2 (en) | 2018-02-20 |
| MX2014013826A (es) | 2018-04-24 |
| CA2873572C (fr) | 2021-07-06 |
| CA2873572A1 (fr) | 2013-11-21 |
| JP6247685B2 (ja) | 2017-12-13 |
| EP2849770A1 (fr) | 2015-03-25 |
| JP2015517522A (ja) | 2015-06-22 |
| EP2849770B1 (fr) | 2020-07-29 |
| US20150080353A1 (en) | 2015-03-19 |
| WO2013172999A1 (fr) | 2013-11-21 |
| AU2013263292B2 (en) | 2018-03-08 |
| EP2849770A4 (fr) | 2016-03-23 |
| AU2013263292A1 (en) | 2015-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10322A (fr) | ||
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| MX2020000984A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
| EP3147285A3 (fr) | Composés de purinone en tant qu'inhibiteurs de kinase | |
| MX350589B (es) | Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia. | |
| BR112014009092A2 (pt) | dispersão sólida | |
| MX2015000337A (es) | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. | |
| MX355833B (es) | Metodo y formulacion para inhalacion. | |
| WO2012101639A3 (fr) | Nanoparticules pour l'administration dermique et systémique de médicaments | |
| CO7310520A2 (es) | Nanopartícula polimérica de finasterida y minoxidil proceso de preparación, suspensión acuosa conteniendo la misma,composición farmaceútica y su uso | |
| MX2014011815A (es) | Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso. | |
| IN2012DN01216A (fr) | ||
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
| WO2011143201A3 (fr) | Administration de médicaments combinatoire ratiométrique | |
| JOP20200109A1 (ar) | مستحضر قابل للحقن | |
| BR112014033115A2 (pt) | pós de polímero solúveis em água com capacidade de dispersão melhorada | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
| MX2012000954A (es) | Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. | |
| MX371349B (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| WO2012092486A3 (fr) | Formulations de benzimidazole à libération modifiée | |
| IN2014DN09416A (fr) | ||
| WO2018229093A8 (fr) | Nanoparticules à titre de véhicules d'administration de principes actifs et leurs procédés de production | |
| WO2013038195A3 (fr) | Compositions de nanoparticules pharmaceutiques |